Literature DB >> 32974944

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

Robert Cornell1, Parameswaran Hari2, Shijie Tang3, Noa Biran4, Natalie Callander5, Ajai Chari6, Saurabh Chhabra2, Mark A Fiala7, Zhubin Gahvari8, Ujjawal Gandhi9, Kelly Godby10, Ridhi Gupta11, Sundar Jagannath12, Megan Jagosky13, Yubin Kang14, Ankit Kansagra15, Michael Kauffman3, Saranya Kodali16, Shaji K Kumar17, Arjun Lakshman18, Michaela Liedtke11, Sagar Lonial19, Xiwen Ma3, Ehsan Malek20, Joshua Mansour21,22, Elizabeth F McGehee15, Amarendra Neppalli23, Barry Paul13, Paul Richardson24, Emma C Scott25, Sharon Shacham3, Jatin Shah3, David S Siegel26, Elvira Umyarova16, Saad Z Usmani13, William Varnado10, Ravi Vij7, Luciano Costa10.   

Abstract

Entities:  

Year:  2020        PMID： 32974944     DOI： 10.1002/ajh.26010

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

Review 1.  The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.

Authors:  Mark Sellin; Stephanie Berg; Patrick Hagen; Jiwang Zhang
Journal:  Transl Oncol       Date:  2022-06-01       Impact factor: 4.803

2.  [COVID-19 in obstetric anesthesia : Prospective surveillance of peripartum infections with SARS-CoV-2 and peripartum course of disease in affected women].

Authors:  Magdalena Sitter; Tobias Schlesinger; Ann-Kristin Reinhold; Axel Scholler; Christian von Heymann; Sabine Welfle; Catharina Bartmann; Achim Wöckel; Stefan Kleinschmidt; Sven Schneider; André Gottschalk; Susanne Greve; Julius Z Wermelt; Roland Wiener; Frank Schulz; Daniel Chappell; Maya Brunner; Claudia Neumann; Patrick Meybohm; Peter Kranke
Journal:  Anaesthesiologie       Date:  2021-11-23

Review 3.  Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.

Authors:  Hashim Mann; Raymond L Comenzo
Journal:  Onco Targets Ther       Date:  2022-07-22       Impact factor: 4.345

4.  I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients.

Authors:  Sarvarinder K Gill; Rashmi Unawane; Shuqi Wang; Jaeil Ahn; Adolfo Aleman; David S Siegel; David H Vesole; Harsh Parmar; Pooja Phull; Noa Biran
Journal:  Blood Cancer J       Date:  2022-09-23       Impact factor: 9.812

5.  KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.

Authors:  Sundar Jagannath; Yi Lin; Hartmut Goldschmidt; Donna Reece; Ajay Nooka; Alicia Senin; Paula Rodriguez-Otero; Ray Powles; Kosei Matsue; Nina Shah; Larry D Anderson; Matthew Streetly; Kimberly Wilson; Hoa Van Le; Arlene S Swern; Amit Agarwal; David S Siegel
Journal:  Blood Cancer J       Date:  2021-06-18       Impact factor: 11.037
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.